Janssen EMEA Receives Conditional Marketing Authorisation fo

For EU Trade and Medical Media Only. Not to Be Distributed to UK and Benelux Based Media Conditional Marketing Authorisation is based on results from the Phase 1 CHRYSALIS study evaluating amivantamab

Related Keywords

Singapore , Italy , Milan , Lombardia , United Kingdom , Noah Reymond , Peter Lebowitz , Jessica Moore , Sarah Jones , Mathai Mammen , Antonio Passaro , None Of The Janssen Pharmaceutical Companies , Janssen Biotech Inc , European Commission , Drug Administration , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Janssen Research Development , Exchange Commission , European Union , Companies Of Johnson , European Medicines Agency , Johnson , Medical Media , Benelux Based , Marketing Authorisation , Conditional Marketing Authorisation , First Treatment Approved , Mutations After Failure , Medical Oncologist , Thoracic Oncology , European Institute , Global Therapeutic Area Head , Global Head , Response Evaluation Criteria , Solid Tumours Version , Solid Tumours , Non Small Cell Lung Cancer , Pharmaceutical Companies , Cardiovascular Metabolism , Infectious Diseases Vaccines , Research Development , Janssen Biotech , Concerning Forward Looking Statements , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Report , Human Bispecific , Met Antibody , Accessed November , Rybrevant Summary , Transduct Target Ther , Mutated Non Small Cell Lung Cancer Progressing , Initial Results From , European Medicines , First Targeted Treatment , Novel Bispecific Antibody Targeting , Met Is Effective , Resistant Lung , Diverse Models , Met Bispecific Antibody , Induces Receptor Downmodulation , Antitumor Activity , Mol Cancer , Participants With Advanced Non Small Cell Lung , Combination With Amivantamab , Lazertinib Combination Therapy Versus Osimertinib , Locally Advanced , Metastatic Non Small Cell Lung Cancer , Patients With Epidermal Growth Factor Receptor , Mutated Locally Advanced , Cell Lung Cancer After Osimertinib Failure , Combination Amivantamab , Carboplatin Pemetrexed Therapy , Compared With Carboplatin Pemetrexed , Participants With Advanced , Epidermal Growth Factor Receptor , Amivantamab Subcutaneous , Advanced Solid , Lung Cancer Res , Year Survival , Mutant Metastatic Lung Adenocarcinoma Treated , World Conference , Lung Cancer Annual Meeting , Janssen , Mea , Eceives , Onditional , Marketing , Authorisation , Rybrevant , Amivantamab , First , Treatment , Approved , Patients , Ith , Dvanced , Mall , Fell , Young , Dancer , Nsclc , Egfr , Exon , Insertion , ,